Completed PHASE1 INTERVENTIONAL 4-arm NCT00070070

Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas

NY-ESO-1 Protein Immunization of Post-Cystectomy or Post-Nephroureterectomy Patients With Transitional Cell Carcinomas

Sponsor: Ludwig Institute for Cancer Research

Interventions NY-ESO-1 protein TICE®-strain BCG sargramostim

Updated 9 times since 2017 Last updated: Oct 3, 2022 Started: Oct 28, 2003 Primary completion: Jan 3, 2006 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00070070, this PHASE1 trial focuses on Transitional Cell Carcinoma and remains completed. Sponsored by Ludwig Institute for Cancer Research, it has been updated 9 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Nov 2022 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 4 earlier versions

Sep 2021 — Nov 2022 [monthly]

Completed PHASE1
Jan 2021 — Sep 2021 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Oct 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Data source: Ludwig Institute for Cancer Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States